← Back to Search

Telerehabilitation using the KinexConnect system for rehabilitation after TKA. for Osteoarthritis (KCTRS Trial)

N/A
Waitlist Available
Led By Barron Bremner, DO
Research Sponsored by Kinex Medical Company, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

KCTRS Trial Summary

This trial found that telerehabilitation with KinexConnect is just as effective as traditional outpatient PT for patients undergoing TKA.

KCTRS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the Timed up and Go (TUG) Test score
Economic Benefit
Secondary outcome measures
Change in Active Range of Motion (ARoM)
Change in Pain as measured by the Verbal Descriptive Scale (VDS)
Change in Passive Range of Motion (PRoM)
+2 more

KCTRS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: KinexConnectExperimental Treatment1 Intervention
Rehab at Home Patients
Group II: Outpatient PTActive Control1 Intervention
In-person PT patients

Find a Location

Who is running the clinical trial?

Kinex Medical Company, LLCLead Sponsor
Health Factors IncUNKNOWN
Barron Bremner, DOPrincipal InvestigatorDes Moines Orthopedic Suregons

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies available to partake in this research endeavor?

"The clinicaltrials.gov records reveal that this medical trial has completed its recruitment period and is no longer seeking patients. The original posting date of the study was November 1st 2019 and it last updated on June 21st 2022. Nevertheless, there are presently 456 other trials open for enrollment at the moment."

Answered by AI

What is the principal aim of this trial?

"The primary efficacy endpoint of this trial, which is set to be measured over a 12 month period, will assess the economic benefit. Secondary endpoints are Change in Passive Range of Motion (PRoM), Change in Active Range of Motion (ARoM) and Verbal Descriptive Scale-based Pain Intensity Levels (VDS). PRoM denotes the range between maximum flexion and extension during passive force application by a clinician; ARoM describes patient's independent effort for achieving max flexion or extension; VDS reflects self-reports on pain intensity with seven verbal cues ranging from no pain to most intense imaginable agony"

Answered by AI
Recent research and studies
~11 spots leftby Mar 2025